NO955189D0 - En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet - Google Patents

En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet

Info

Publication number
NO955189D0
NO955189D0 NO955189A NO955189A NO955189D0 NO 955189 D0 NO955189 D0 NO 955189D0 NO 955189 A NO955189 A NO 955189A NO 955189 A NO955189 A NO 955189A NO 955189 D0 NO955189 D0 NO 955189D0
Authority
NO
Norway
Prior art keywords
kgf
abbreviated
keratinocyte growth
growth factor
biological activity
Prior art date
Application number
NO955189A
Other languages
English (en)
Norwegian (no)
Other versions
NO955189L (no
Inventor
Denis Gospodarowicz
Frank Masiarz
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO955189D0 publication Critical patent/NO955189D0/no
Publication of NO955189L publication Critical patent/NO955189L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
NO955189A 1993-06-29 1995-12-20 En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet NO955189L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (2)

Publication Number Publication Date
NO955189D0 true NO955189D0 (no) 1995-12-20
NO955189L NO955189L (no) 1995-12-20

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO955189A NO955189L (no) 1993-06-29 1995-12-20 En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet

Country Status (25)

Country Link
US (7) US5677278A (sk)
EP (2) EP1493812A3 (sk)
JP (4) JP3570516B2 (sk)
KR (1) KR960703433A (sk)
CN (1) CN1129955A (sk)
AT (1) ATE278777T1 (sk)
AU (1) AU681405B2 (sk)
BG (1) BG100236A (sk)
BR (1) BR9407035A (sk)
CA (1) CA2166278A1 (sk)
CZ (1) CZ343795A3 (sk)
DE (2) DE122006000005I2 (sk)
DK (1) DK0706563T3 (sk)
ES (1) ES2227527T3 (sk)
FI (1) FI956203A (sk)
FR (1) FR06C0004I2 (sk)
HU (1) HUT73453A (sk)
LU (1) LU91215I2 (sk)
NL (1) NL300217I2 (sk)
NO (1) NO955189L (sk)
NZ (1) NZ266622A (sk)
PL (1) PL312257A1 (sk)
PT (1) PT706563E (sk)
SK (1) SK153295A3 (sk)
WO (1) WO1995001434A1 (sk)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008771A1 (en) 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
WO1995001434A1 (en) * 1993-06-29 1995-01-12 Chiron Corporation A truncated keratinocyte growth factor (kgf) having increased biological activity
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
CN1168678A (zh) * 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
DE69530599T2 (de) * 1994-10-13 2003-11-13 Amgen Inc., Thousand Oaks Methode zur reinigung von keratinocyten-wachstumsfaktoren
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
PT1486565E (pt) * 1995-10-11 2008-02-28 Novartis Vaccines & Diagnostic Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
DE69728415T2 (de) * 1996-10-15 2004-08-12 Amgen Inc., Thousand Oaks Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
JP2002513294A (ja) * 1997-06-19 2002-05-08 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
EP1041996A4 (en) * 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CA2320515A1 (en) * 1998-02-13 1999-08-19 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
AU2039501A (en) 1999-10-15 2001-04-23 Rockefeller University, The System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
AU2002236477A1 (en) 2000-11-21 2002-06-03 The Texas A & M University System Fgf-affinity chromatography
AU2002309473A1 (en) * 2001-01-08 2002-10-08 Human Genome Sciences, Inc. Keratinocyte growth factor-2
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
PL374269A1 (en) * 2001-08-21 2005-10-03 Chiron Corporation Kgf polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
JP5201992B2 (ja) * 2004-12-15 2013-06-05 バイオビトラム・アクテイエボラーグ(パブリツク) ケラチノサイト増殖因子の治療用製剤
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
EP2454368A4 (en) 2009-07-17 2013-01-09 Aaron Thomas Tabor COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE
CA2928526A1 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CN117858717A (zh) 2021-08-30 2024-04-09 联合化学实验室有限公司 用于治疗炎症性疾病的蛋白质组合物
KR102691028B1 (ko) * 2021-11-15 2024-08-05 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008771A1 (en) 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5965530A (en) 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
WO1995001434A1 (en) 1993-06-29 1995-01-12 Chiron Corporation A truncated keratinocyte growth factor (kgf) having increased biological activity
CN1168678A (zh) 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法
SI0785950T1 (en) 1994-10-13 2003-08-31 Amgen Inc. Keratinocyte growth factor analogs

Also Published As

Publication number Publication date
CN1129955A (zh) 1996-08-28
FI956203A (fi) 1996-02-07
US5677278A (en) 1997-10-14
JP2009062396A (ja) 2009-03-26
JPH09500267A (ja) 1997-01-14
AU681405B2 (en) 1997-08-28
LU91215I2 (en) 2006-03-27
BR9407035A (pt) 1996-03-12
JP4662569B2 (ja) 2011-03-30
US20090093400A1 (en) 2009-04-09
CA2166278A1 (en) 1995-01-12
DE69434053D1 (de) 2005-01-20
HU9503857D0 (en) 1996-02-28
FI956203A0 (fi) 1995-12-22
JP2006075173A (ja) 2006-03-23
JP3570516B2 (ja) 2004-09-29
EP0706563A1 (en) 1996-04-17
AU6820894A (en) 1995-01-24
NL300217I1 (nl) 2006-04-03
NO955189L (no) 1995-12-20
FR06C0004I1 (sk) 2006-03-10
PT706563E (pt) 2005-01-31
BG100236A (en) 1996-07-31
US5773586A (en) 1998-06-30
EP1493812A3 (en) 2006-02-08
US6677301B1 (en) 2004-01-13
DE122006000005I1 (de) 2006-08-10
EP1493812A2 (en) 2005-01-05
DK0706563T3 (da) 2005-01-31
FR06C0004I2 (fr) 2006-12-29
WO1995001434A1 (en) 1995-01-12
DE122006000005I2 (de) 2006-11-23
EP0706563B1 (en) 2004-10-06
KR960703433A (ko) 1996-08-17
PL312257A1 (en) 1996-04-01
US5843883A (en) 1998-12-01
DE69434053T2 (de) 2006-02-23
NL300217I2 (nl) 2006-05-01
NZ266622A (en) 1997-10-24
US6074848A (en) 2000-06-13
JP2004166709A (ja) 2004-06-17
HUT73453A (en) 1996-08-28
CZ343795A3 (en) 1996-07-17
ES2227527T3 (es) 2005-04-01
SK153295A3 (en) 1996-11-06
ATE278777T1 (de) 2004-10-15
US5863767A (en) 1999-01-26

Similar Documents

Publication Publication Date Title
NO955189D0 (no) En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
ATE139569T1 (de) Modifizierter, menschlicher gewebeplasminogenaktivator und seine herstellung
ATE133200T1 (de) Modifiziertes, biologisch aktives protein
ES2184728T3 (es) Proteinas de union a la fibronectina.
DE69024104D1 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
ATE166359T1 (de) Peptide mit einer lanthionin-brücke
ATE153069T1 (de) Vektoren und zusammensetzungen zur expression von glykosilationsmutanten des menschlichen proteins- c
BR8907842A (pt) Artropodicidas de semicarbazona substituida
ATE209252T1 (de) Rekombinante d-hydantoinase, verfahren zur herstellung und verwendung
PT90504A (pt) Processo para a preparacao de alcoois peptidicos com actividade anticoagulante
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
IT1231764B (it) Composizione poliuretanica con capacita' di assorbire umidita', particolarmente adatta per la fabbricazione di cuoio sintetico e simili, e procedimento per la sua produzione.
EP0254272A3 (en) The use of probucol for preventing and treating heart diseases
CA2067176A1 (en) Recombinant gene coding for a protein having an endochitinase activity
AU6860294A (en) New chondrocyte proteins
EP0206329A3 (en) Sprung floor
AU4315396A (en) Monoclonal antibody
DE69534056D1 (de) Neue staphylokinase Derivate
DK51893D0 (da) 1,2,3-thiadiazol-4-thio-forbindelser
MX9604896A (es) Mejoramientos en o relacionados a la resistencia de las plantas contra enfermedades.